Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
One month after vaccination: For Subjects of two years of age and above • To evaluate the non-inferiority of the MenACWY-TT conjugate vaccine compared to the licensed Mencevax ACWY in terms of the vaccine response to MenA, MenC, MenY and MenW-135* *Response to a vaccine antigen component is defined as : - for initially seronegative subject, post vaccination rSBA titer ≥ 1:32 - for initially seropositive subject, at least 4-fold increase in rSBA titre from pre to post vaccination For Subjects below two years of age • To evaluate the non-inferiority of the vaccine response induced by the MenACWY-TT conjugate vaccine when compared to the licensed Meningitec vaccine for N. meningitidis serogroup C as measured by serum bactericidal antibodies (rSBA). • To evaluate the immunogenicity induced by the MenACWY-TT conjugate vaccine when compared to the licensed Meningitec vaccine for N. meningitidis serogroups A, W-135, and Y as measured by rSBA.
Inclusion criteria
- Primary immunization of healthy subjects aged 1 through 10 years against meningococcal disease due to serogroup A, C, W-135 or Y